Wall Street Zen upgraded shares of Pediatrix Medical Group (NYSE:MD – Free Report) from a buy rating to a strong-buy rating in a research note issued to investors on Sunday,Wall Street Zen reports.
Other equities analysts also recently issued research reports about the company. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $25.00 price target on shares of Pediatrix Medical Group in a research report on Wednesday, August 5th. Truist Financial upped their price objective on Pediatrix Medical Group from $23.00 to $28.00 and gave the company a “hold” rating in a research report on Tuesday, July 14th. UBS Group increased their price objective on Pediatrix Medical Group from $25.00 to $28.00 and gave the company a “neutral” rating in a research note on Thursday, August 6th. Weiss Ratings upgraded Pediatrix Medical Group from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, September 9th. Finally, Jefferies Financial Group downgraded shares of Pediatrix Medical Group from a “buy” rating to a “hold” rating and boosted their target price for the company from $27.00 to $28.00 in a research note on Wednesday, August 19th. One analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Pediatrix Medical Group has a consensus rating of “Hold” and an average price target of $26.60.
Read Our Latest Research Report on Pediatrix Medical Group
Pediatrix Medical Group Stock Down 0.8%
Pediatrix Medical Group (NYSE:MD – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.59 by $0.04. Pediatrix Medical Group had a net margin of 8.96% and a return on equity of 20.05%. The business had revenue of $487.78 million for the quarter, compared to analyst estimates of $478.49 million. During the same period in the prior year, the business earned $0.53 earnings per share. The company’s quarterly revenue was up 4.1% on a year-over-year basis. Equities analysts anticipate that Pediatrix Medical Group will post 2.17 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the business. BlackRock Inc. acquired a new position in shares of Pediatrix Medical Group during the 2nd quarter valued at about $347,383,000. Wasatch Advisors LP purchased a new position in shares of Pediatrix Medical Group during the 1st quarter worth about $43,861,000. Bank of New York Mellon Corp acquired a new stake in shares of Pediatrix Medical Group in the second quarter worth approximately $14,297,000. Rockefeller Capital Management L.P. boosted its position in shares of Pediatrix Medical Group by 814.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 594,351 shares of the company’s stock worth $12,713,000 after acquiring an additional 529,367 shares during the last quarter. Finally, Empowered Funds LLC purchased a new stake in Pediatrix Medical Group in the second quarter valued at approximately $12,668,000. Hedge funds and other institutional investors own 97.71% of the company’s stock.
About Pediatrix Medical Group
Pediatrix Medical Group, Inc is a physician-led healthcare services company that provides specialized medical care for women, infants and children. The company partners with hospitals and health systems to deliver care through physician practices, neonatal intensive care units and other hospital-based programs.
Its services include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric hospital medicine and other pediatric subspecialties. Pediatrix physicians care for patients before, during and after childbirth, as well as children requiring specialized or critical care.
Read More
- Five stocks we like better than Pediatrix Medical Group
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for Pediatrix Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pediatrix Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.
